Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
Study Identifier:
ECU-MG-302
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Eculizumab
- Drug: Placebo
Date
Nov 2014 - Jan 2019
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Biological: Eculizumab
- Drug: Placebo
Date
Nov 2014 - Jan 2019
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
To evaluate the safety and efficacy of eculizumab in the treatment of refractory generalized myasthenia gravis (gMG) as an extension study for the participants who previously completed Study ECU-MG-301(NCT01997229).
Trial Locations
Location
Status
Location
Birmingham, Alabama, United States, 35233
Status
N/A
Location
Los Angeles, California, United States, 90033
Status
N/A
Location
Orange, California, United States, 92868
Status
N/A
Location
Palo Alto, California, United States, 94304
Status
N/A
Location
San Francisco, California, United States, 94115
Status
N/A
Location
New Haven, Connecticut, United States, 06519
Status
N/A